Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors derived from chromaffin cells in the autonomic nervous system. Depending on their location, these tumors are capable of excessive catecholamine production, which may lead to uncontrolled hypertension and other life-threatening complications. They are associated with a significant risk of metastatic disease and are often caused by an inherited germline mutation. Although surgery can cure localized disease and lead to remission, treatments for metastatic PPGL (mPPGL)-including chemotherapy, radiopharmaceutical agents, multikinase inhibitors, and immunotherapy used alone or in combination- aim to control tumor growth and limit organ damage. Substantial advances have been made in understanding hereditary and somatic molecular signaling pathways that play a role in tumor growth and metastasis. Treatment options for metastatic disease are rapidly evolving, and this paper aims to provide a brief overview of the management of mPPGL with a focus on therapy options.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- clinical practice
- neuroendocrine tumors
- blood pressure
- signaling pathway
- minimally invasive
- rheumatoid arthritis
- oxidative stress
- radiation therapy
- risk factors
- body mass index
- systemic lupus erythematosus
- disease activity
- cell cycle arrest
- epithelial mesenchymal transition
- single molecule
- rectal cancer
- weight gain
- atrial fibrillation
- cell therapy